91 results about "Coboglobin" patented technology

The invention provides a hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit comprises an upper shell, a lower shell, an immunostrip, test paper and the like; a gold-labeled composite containing a hemoglobin monoclonal antibody, a hemoglobin-haptoglobin composite monoclonal antibody and a transferrin monoclonal antibody is scribed on a nitrocellulose membrane; 3 test lines, a quality control line (15) and a gold-labeled composite membrane scribing line (8) are arranged on the nitrocellulose membrane in parallel. The invention further provides a preparation method and a detection method of the hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit is convenient and simple in operation, stable in performance and accurate in result, has a relatively good reference value for early diagnosis and identification of colorectal cancer or colon cancer tumor or other tumors with lower gastrointestinal bleeding symptoms in clinic, significantly improves the positive detection rate of digestive hemorrhagic diseases, is suitable for clinical hospital examination and household self-examination, and provides measures for large-scale general examination of such diseases.

The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.

Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments.

The invention belongs to the field of biological chemical detection and particularly relates to a method of determining the ratio of a globin chain alpha to a globin chain beta in hemoglobin and application of the method in detection of beta-mediterranean anemia. The method comprises the steps that hemoglobin samples are taken and split to obtain split fragments of the globin chain alpha and split fragments of the globin chain beta; one split fragment of the globin chain alpha and one split fragment of the globin chain beta are selected and used as sign peptide fragments; a mass spectrum is used for determining the concentration of the sign peptide fragment of the globin chain alpha and the concentration of the sign peptide fragment of the globin chain beta; the ratio of the globin chain alpha to the globin chain beta is expressed just by the ratio of the concentration of the sign peptide fragment of the globin chain alpha to the concentration of the sign peptide fragment of the globin chain beta. According to the method, by means of quantitative analysis of the ratio of the globin chain alpha to the globin chain beta, different types of beta-mediterranean anemia can be identified at an early stage, and severe, medium and mild beta-mediterranean anemia can be identified.

Provided herein are methods for the diagnosis of obstructive airways diseases such as asthma and chronic obstructive pulmonary disease, and the discrimination between such diseases based on the expression profiles of biomarker proteins and combinations of biomarker proteins. In particular embodiments the biomarker proteins are selected from ceruloplasmin, haptoglobin, hemopexin, -2-macroglobulin, prothrombin, immunoglobulin A and complement factor H.

The invention discloses a method for separating copper proteome by using copper-chelated magnetic beads, and relates to the technical field of protein chemistry. The method comprises the following steps: taking a biological tissue or cell, after fully grinding with liquid nitrogen, adding protein extracting liquid, and after uniformly mixing, carrying out low-temperature centrifugation, so as to obtain a denatured protein solution; mixing the copper-chelated magnetic beads with the denatured protein solution, and incubating to obtain a magnetic bead protein mixed solution; adding a buffer solution 1 with the volume 1 time of that of the magnetic bead protein mixed solution into the magnetic bead protein mixed solution for suspension, pouring half of the supernate under the external magnetic field, and repeating for 4-5 times to obtain a mixed solution A; adding a buffer solution 2 with the volume 1 time of that of the mixed solution A into the mixed solution A, separating all the specific copper-binding proteins, namely, the copper proteome, and collecting the copper proteome under the external magnetic field. According to the method, the metalloproteome is separated under a denaturing condition by using magnetic bead-IDA, so that the procedures are greatly simplified, and the obtaining efficiency of metalloproteins is improved; a method suitable for separating the metalloproteome from the tissue or cell under the excess heavy metal treatment condition is established.

Disclosed is a test paper for detection of diabetic nephropathy, which includes a water-absorbing filter paper, a glass fiber membrane and a NC membrane, all of which are stacked successively from top to bottom. The test paper has a T1 testing region, a T2 testing region and a T3 reference region arranged along a transverse direction; the NC membrane is coated by urinary microalbumin antibodies in the T1 testing region, is coated by urinary haptoglobin antibodies in the T2 testing region and is coated by mouse anti-human IgG antibodies in the T3 reference region; and the glass fiber membrane is coated by urinary microalbumin labeled with colloidal gold in the T1 testing region, is coated by urinary haptoglobin labeled with colloidal gold in the T2 testing region and is coated by mouse anti-human IgG albumen labeled with colloidal gold in the T3 reference region.

The present invention relates to genetically edited swine which produce CD163 protein in which the scavenger receptor cysteine-rich 5 (SRCR5) domain (also known as CD163 domain 5) has been deleted. Such swine have been found to be healthy and do not exhibit negative properties, and are resistant to PRRSV infection. CD163 expressed in the edited swine also demonstrates retention of the ability to function as a haemoglobin-haptoglobin scavenger. Methods of producing such swine are also provided.

Compositions that include a globin, such as hemoglobin, in a relaxed state are described. Globin molecules in a relaxed state (R state) have a higher binding affinity for carbon monoxide and oxygen than globin molecules in a tense state (T state). Hemoglobin in a relaxed state can be, for example, hemoglobin that is substantially free of 2,3-diphosphoglycerate or hemoglobin that includes a beta-Cys93 that is covalently modified to inhibit one or both salt bridges between beta-Asp94, beta-His146 and alpha-Lys40. Methods for using these compositions, such as for treating carbon monoxide poisoning, and methods for producing these compositions, are also disclosed.

The invention provides a cytokine-induced killer cell activity-associated protein and an application thereof, relates to an immune cell activity-associated protein and especially relates to influences of haptoglobin on variation of cell activity of cytokine-induced killer (CIK) cells. The expression of the haptoglobin at a protein level and a nucleic acid level is significantly increased with enhancement of the activity of the CIK cells, which means that a positive correlativity exists between the haptoglobin and the activity of the cytokine-induced killer cells. The invention provides an index of detection of an activity intensity of the CIK cells, or provides basis for researching a recombinant protein and a relative medicine which are used for improving an immune system with the haptoglobin as an active component.

The present invention provides an anti-hypertensive agent. The anti-hypertensive agent of the present invention contains, as an active ingredient, at least one peptide selected from the group consisting of peptides originally derived from globin proteolysate, each of which consists of one of the following amino acid sequences (1) to (6), or a globin proteolysate containing at least one of the peptides: (1) Val-Val-Tyr-Pro (SEQ ID: NO. 1); (2) Trp-Gly-Lys-Val-Asn (SEQ ID: NO. 2); (3) Trp-Gly-Lys-Val (SEQ ID: NO. 3); (4) Trp-Gly-Lys (SEQ ID: NO. 4); (5) Ala-Ala-Trp-Gly-Lys (SEQ ID: NO. 5); and (6) Phe-Glu-Ser (SEQ ID: NO. 6).

The invention relates to the technical field of immunodiagnosis, and discloses colloidal gold immunochromatography test paper for rapidly diagnosing hemoglobin and haptoglobin hemoglobin complex and apreparation method thereof, aiming at the problem of inaccurate detection result caused by easy damage of pepsase to hemoglobin in digestive tracts in the prior art. The method specifically comprisesthe following steps: 1) preparing a first detection line T and a first quality control line C; 2) preparing a second detection line T and a second quality control line C; 3) preparing a gold-labeledpad; 4) preparing the test paper: sequentially connecting and assembling the water absorption pad, the sample pad, the microsphere probe treatment pad, the antibody-coated modified nitrocellulose membrane and the PVC bottom plate to obtain a finished product. The hemoglobin and hemoglobin combined globin compound is adopted for combined detection, the detection sensitivity of occult blood including upper gastrointestinal hemorrhage is improved, operation is easy, convenient and rapid, the result is visually and accurately displayed, sensitivity is high, specificity is good, and the preparationprocess is simple.

The present invention provides a method of stabilizing a protein. The method includes a step of causing a protein contained in a specimen derived from a living body to coexist with an arylboronic acid. The protein contained in the specimen derived from the living body is at least one type selected from the group consisting of hemoglobin, haptoglobin, and a hemoglobin-haptoglobin complex. According to the present invention, it is possible to stabilize a protein such as a blood protein contained in the specimen derived from a living body. The present invention further provides a stabilizing solution for stabilizing a protein contained in a specimen derived from a living body and a method and a kit for detecting a protein contained in a specimen derived from a living body.

The present disclosure provides expression vectors comprising at least two nucleic acid sequences, namely a nucleic acid sequence encoding an anti-HPRT RNAi, and a nucleic acid sequence encoding a gamma globin gene. In some embodiments, the viral vector is a self-inactivating lentiviral vector. In some embodiments, the gamma-globin gene is used to genetically correct sickle cell disease or β-thalassemia or to reduce symptoms thereof.

The invention discloses a product used for treating and/or preventing beta hemoglobinopathy and a fusion protein. The fusion protein comprises a DNA binding structural domain of Rad51, a cytosine deaminase APOBEC3A mutant and nuclease, the cytosine deaminase APOBEC3A mutant means that asparagine at the 57th site of cytosine deaminase APOBEC3A is mutated into glycine. The product comprises a coding gene of the fusion protein and a delivery vector of sgRNA, and the sgRNA guides the fusion protein to carry out single-base gene editing on HBG1 and HBG2 promoter regions in target cells. According to the product used for treating and/or preventing the beta hemoglobinopathy and the fusion protein, the single-base gene editing efficiency can be greatly improved, and the HBG1 and HBG2 promoter region-117 sites are more accurately and efficiently targeted to generate G-to-A mutation, so that the expression of gamma-globin is activated, and a more accurate and efficient treatment strategy is provided for clinical treatment of beta-hemoglobinopathy.

The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.

The invention discloses a chemiluminiscence kit for detecting trace haptoglobin in urine. The chemiluminiscence kit is used for detecting the trace haptoglobin in urine by adopting a double monoclonalantibody sandwich method; the chemiluminiscence kit comprises a chemiluminiscence plate, an enzyme-labeled monoclonal antibody solution, a standard substance solution and a luminescent substrate; thechemiluminiscence plate is coated with a diluted monoclonal antibody 5C4 and is sealed by a confining liquid; the enzyme-labeled monoclonal antibody solution is prepared from a monoclonal antibody HRP-1A2 labeled by HRP and an antibody diluent; and the monoclonal antibody 5C4 and the monoclonal antibody 1A2 are monoclonal antibodies capable of recognizing human natural Hp molecular structure epitopes. According to the chemiluminiscence reagent, the double monoclonal antibody sandwich method is adopted to detect a content of Hp in the urine; and the monoclonal antibodies 5C4 and 1A2 are used as double single antibodies, the pair of monoclonal antibodies can specifically recognize human Hp molecular structure epitopes, structural epitope antibodies can specifically detect non-denatured Hp molecules, detection accuracy is high, and a bias value is-6.78%-10.12%.

The invention discloses a characteristic protein marker composition for screening thalassemia, a mass spectrum model and application thereof. The invention firstly discloses a characteristic protein marker composition for screening thalassemia. The composition comprises alpha globin, beta globin, delta globin, gamma globin and/or carbonic anhydrase I, and the sequences of the alpha globin, the beta globin, the delta globin, the gamma globin and/or the carbonic anhydrase I are respectively shown as SEQ ID NO.1-5. The invention further discloses a mass spectrum model containing the marker composition and application of the mass spectrum model in preparation of products for screening thalassemia. Based on the MALDI-TOF mass spectrum technology, the method can screen beta thalassemia by analyzing the mass spectrum peak areas and ratios of different characteristic proteins, carries alpha and beta thalassemia, alpha thalassemia and abnormal hemoglobin samples, and has the characteristics ofsimple sample pretreatment, high detection flux, less reagent consumables, low cost, less sampling amount, high sensitivity and the like; and large-scale population screening can be carried out in regions with high occurrence rate of thalassemia.

The invention provides application of a thyroid hormone and an analogue thereof in preparation of drugs for treating a sickle-cell disease, and particularly relates to application in regulation and control of zeta-globin gene expression. In the K562 cell differentiation process, the thyroid hormone analogue can specifically and remarkably up-regulate the expression of zeta-globin gene (HBZ) by more than 50 times; and after treatment is carried out in a zebra fish embryo of a model animal by the thyroid hormone and the analogue thereof, the expression of the zeta-globin gene (hbae5) can also bespecifically up-regulated by more than 30-70 times. Therefore, the thyroid hormone and the analogue thereof disclosed by the invention can specifically activate the expression of the zeta-globin gene, namely, the silent zeta-globin gene in the body of a sickle-cell disease patient is reactivated to inhibit sickle hemoglobin S polymerization reaction, the thyroid hormone and the analogue become amethod for preparing the drugs for treating the sickle-cell disease, an economical, safe and effective method is provided for treatment of the sickle-cell disease, and the method can be widely appliedand popularized.